<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00496067</url>
  </required_header>
  <id_info>
    <org_study_id>300-06-008</org_study_id>
    <nct_id>NCT00496067</nct_id>
  </id_info>
  <brief_title>Uterine Artery Occlusion for Fibroid Related Bleeding</brief_title>
  <official_title>An Evaluation of a Doppler-Guided Uterine Artery Occlusion Device as Treatment for the Reduction of Fibroid-Associated Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ethicon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ethicon, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and effectiveness of Doppler&#xD;
      guided Uterine Artery Occlusion (D-UAO) as treatment for the reduction of fibroid-associated&#xD;
      symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DUAO is intended for bilateral occlusion of the uterine arteries&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Data required further pilot work to be undertaken.&#xD;
  </why_stopped>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lack of surgical re-intervention</measure>
    <time_frame>Post-op through end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with improvement in Uterine Fibroid Symptom Quality of Life (UFS-QOL) Symptom Severity and Health Related Quality of Life (HRQL) scores.</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean improvement in UFS-QOL Symptom Severity and HRQL transformed scores.</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean HRQL subscales.</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with reduction of 50% or greater in Pictorial Blood Loss Assessment Chart (PBLAC) score.</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in PBLAC scores.</measure>
    <time_frame>Baseline to 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with decrease in fibroid load based on independent MRI review.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with maintenance of menses as defined by continuation of menstrual cycles without an interruption of three consecutive months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with procedural satisfaction as defined by responses of either satisfied or very satisfied.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lack of surgical re-intervention.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>Discharge or 24-hour post clamp removal, whichever is earlier</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to normal activities (household, work and sexual intercourse)</measure>
    <time_frame>Post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro-QOL expressed as change from baseline for each of the 6 domains and Visual Analogue Scale (VAS)</measure>
    <time_frame>1, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nights in hospital</measure>
    <time_frame>Total and post procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Menorrhagia</condition>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DUAO Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Doppler-Guided Uterine Artery Occlusion Device</intervention_name>
    <description>For bilateral occlusion of the uterine arteries</description>
    <arm_group_label>1</arm_group_label>
    <other_name>floSTAT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  25 to 50 years of age&#xD;
&#xD;
          -  Subject has a negative urine or blood pregnancy test prior to the procedure. At the&#xD;
             time of enrollment to the study, the subject has no intent of further childbearing and&#xD;
             intends to use appropriate contraception throughout the first 12 months of the study&#xD;
             period (unless sterilized)&#xD;
&#xD;
          -  Normal pap smear within 36 months of study procedure (most recent)&#xD;
&#xD;
          -  Cervix suitable for tenaculum placement as determined by pelvic exam (adequate length&#xD;
             of cervix, absence of cervical fibroid/lower fibroid to prevent clamp placement)&#xD;
&#xD;
          -  At least one intra-mural or sub-serosal or sub-mucosal uterine fibroid with a minimum&#xD;
             diameter of greater than or equal to 3 cm, and all fibroids with a diameter less than&#xD;
             or equal to 8cm with a prevailing pathology (e.g., as opposed to adenomyosis) of&#xD;
             fibroids determined through ultrasound&#xD;
&#xD;
          -  Symptomatic subject presenting with at least one of the following fibroid symptoms:&#xD;
             pelvic pressure, menorrhagia, metrorrhagia, pelvic pain, increasing abdominal girth or&#xD;
             dyspareunia due to fibroids.&#xD;
&#xD;
          -  Subject has evidence of bilateral ureteric flow&#xD;
&#xD;
          -  Subject agrees to participate in the study, including completion of all study-related&#xD;
             procedures and evaluations, and documents this agreement by signing the Ethics&#xD;
             Committee-approved informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy as confirmed by positive urine or blood pregnancy test&#xD;
&#xD;
          -  Menopausal as defined by elevated follicle-stimulating hormone (FSH) and decreased&#xD;
             oestradiol hormone levels as determined by the hospital local laboratory reference&#xD;
             range criteria&#xD;
&#xD;
          -  Presence of any pedunculated sub-mucosal or pedunculated sub-serosal fibroid(s) as&#xD;
             determined by MRI, ultrasound or hysteroscopy&#xD;
&#xD;
          -  Presence of an intra-uterine device (IUD)&#xD;
&#xD;
          -  Any hydronephrosis as determined on renal ultrasound prior to the procedure&#xD;
&#xD;
          -  Clinical history of any thrombo-embolic disease or known thrombophilia&#xD;
&#xD;
          -  Blood Urine Nitrogen (BUN) greater than 7.2mmol/L* and/or serum creatinine greater&#xD;
             than 106Î¼mol/L* unresolved with change in diet or hydration&#xD;
&#xD;
          -  History or current evidence of gynecologic malignancy (confirmed by hysteroscopy or&#xD;
             endometrial biopsy), atypical endometrial hyperplasia, or chronic pelvic inflammatory&#xD;
             disease&#xD;
&#xD;
          -  Pelvic mass outside the uterus other than uterine fibroids&#xD;
&#xD;
          -  Any current acute or chronic systemic infection or localized pelvic infection,&#xD;
             including a urinary tract infection&#xD;
&#xD;
          -  Use of Gonadotropin-Releasing Hormone (GnRH) agonist, danozol or mifepristone within&#xD;
             6-months prior to the start of the study procedure&#xD;
&#xD;
          -  Using anticoagulation therapy (except over the counter treatments (e.g. aspirin)), or&#xD;
             have an underlying bleeding disorder&#xD;
&#xD;
          -  Unsuitable for MRI examination (e.g. severe claustrophobia, non-MRI-compatible&#xD;
             implanted metalloid devices)&#xD;
&#xD;
          -  Prior endometrial ablation, uterine artery embolization, or uterine artery ligation&#xD;
&#xD;
          -  Poor procedural candidate due to medical conditions as determined by the investigator&#xD;
             (e.g. anesthesia class, renal insufficiency, heart disease);&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Robinson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ethicon, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Viborg County Hospital</name>
      <address>
        <city>Viborg</city>
        <zip>DK-8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Angers cedex</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Gynecologie Obsterique, Hopital Antoine Beclere</name>
      <address>
        <city>Clamart Cedex</city>
        <zip>92414</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maternite les Bazennes</name>
      <address>
        <city>Dunkerque</city>
        <zip>59430</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille, Hopital Jeanne de Flandre</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaeklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitats-Frauenklinik Tubingen</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ullevaal University</name>
      <address>
        <city>Oslo</city>
        <zip>N-0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitats-Frauenklinik</name>
      <address>
        <city>Bern</city>
        <zip>3012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M1 Maternity, Bradford Royal Infirmary</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull and East Yorkshire Women &amp; Children Hospital</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elizabeth Garret Anderson Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1E 6DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth the Queen Mother Hospital</name>
      <address>
        <city>Margate</city>
        <zip>CT9 4AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>July 3, 2007</study_first_submitted>
  <study_first_submitted_qc>July 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2007</study_first_posted>
  <last_update_submitted>March 8, 2011</last_update_submitted>
  <last_update_submitted_qc>March 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Judi Gauld, Manager Clinical Research</name_title>
    <organization>Ethicon Inc.</organization>
  </responsible_party>
  <keyword>Fibroids</keyword>
  <keyword>Menorrhagia</keyword>
  <keyword>Menorrhagia associated with uterine fibroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Menorrhagia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

